| Autor: |
Elizabeth C. Randall, Kristina B. Emdal, Janice K. Laramy, Minjee Kim, Alison Roos, David Calligaris, Michael S. Regan, Shiv K. Gupta, Ann C. Mladek, Brett L. Carlson, Aaron J. Johnson, Fa-Ke Lu, X. Sunney Xie, Brian A. Joughin, Raven J. Reddy, Sen Peng, Walid M. Abdelmoula, Pamela R. Jackson, Aarti Kolluri, Katherine A. Kellersberger, Jeffrey N. Agar, Douglas A. Lauffenburger, Kristin R. Swanson, Nhan L. Tran, William F. Elmquist, Forest M. White, Jann N. Sarkaria, Nathalie Y. R. Agar |
| Jazyk: |
angličtina |
| Rok vydání: |
2018 |
| Předmět: |
|
| Zdroj: |
Nature Communications, Vol 9, Iss 1, Pp 1-13 (2018) |
| Druh dokumentu: |
article |
| ISSN: |
2041-1723 |
| DOI: |
10.1038/s41467-018-07334-3 |
| Popis: |
Despite major drug discovery efforts, the therapeutic options for glioblastoma (GBM) remain inadequate. Here they analyze patient-derived xenograft model of GBM to quantitatively map distribution and cellular response to the EGFR inhibitor erlotinib, and report heterogeneous erlotinib delivery to intracranial tumors to be inadequate to inhibit EGFR signaling. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
